Indicated to alleviate HIV-1 infection severity by addressing viral integration to support immune health and mitigate the risk of clinical disease progression effectively.
Mechanism of Action
Raltegravir inhibits the HIV integrase enzyme. HIV needs this enzyme to insert its genetic code into the DNA of the host's cells. By blocking this step, the virus is unable to replicate or infect new immune cells.
Route of Administration
Oral
Onset Time
Steady state in 2 days
Duration
12–24 hours (formulation dependent)
Contraindications
Hypersensitivity to raltegravir
Severe Adverse Events
Severe skin reactions (SJS), Muscle breakdown (Rhabdomyolysis), Liver failure, Severe psychiatric symptoms (Depression), Immune reconstitution syndrome
Information for Isentress is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.